Pharma & Healthcare
Global Small Molecule Multi-target Angiogenesis Inhibitor Market Research Report 2026
- Feb 24, 26
- ID: 720929
- Pages: 119
- Figures: 123
- Views: 1
This report delivers a comprehensive overview of the global Small Molecule Multi-target Angiogenesis Inhibitor market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Small Molecule Multi-target Angiogenesis Inhibitor. The Small Molecule Multi-target Angiogenesis Inhibitor market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Small Molecule Multi-target Angiogenesis Inhibitor market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Small Molecule Multi-target Angiogenesis Inhibitor manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Bayer
Teva
TWi Pharmaceuticals
Pfizer
Novartis
AstraZeneca.
Sanofi
Exelixis
Boehringer Ingelheim
Eisai
Janssen Biotech
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Segment by Type
Sorafenib
Sunitinib
Apatinib
Anlotinib
Lenvatinib
Vandetanib
Cabozantinib
Pazopanib
Axitinib
Other
by Application
Cancer Therapy
Ophthalmic Diseases
Inflammatory and Autoimmune Diseases
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Small Molecule Multi-target Angiogenesis Inhibitor manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Small Molecule Multi-target Angiogenesis Inhibitor sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Small Molecule Multi-target Angiogenesis Inhibitor market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Small Molecule Multi-target Angiogenesis Inhibitor manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Bayer
Teva
TWi Pharmaceuticals
Pfizer
Novartis
AstraZeneca.
Sanofi
Exelixis
Boehringer Ingelheim
Eisai
Janssen Biotech
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Segment by Type
Sorafenib
Sunitinib
Apatinib
Anlotinib
Lenvatinib
Vandetanib
Cabozantinib
Pazopanib
Axitinib
Other
by Application
Cancer Therapy
Ophthalmic Diseases
Inflammatory and Autoimmune Diseases
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Small Molecule Multi-target Angiogenesis Inhibitor manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Small Molecule Multi-target Angiogenesis Inhibitor sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Small Molecule Multi-target Angiogenesis Inhibitor Market Overview
1.1 Product Definition
1.2 Small Molecule Multi-target Angiogenesis Inhibitor by Type
1.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type: 2025 vs 2032
1.2.2 Sorafenib
1.2.3 Sunitinib
1.2.4 Apatinib
1.2.5 Anlotinib
1.2.6 Lenvatinib
1.2.7 Vandetanib
1.2.8 Cabozantinib
1.2.9 Pazopanib
1.2.10 Axitinib
1.3 Small Molecule Multi-target Angiogenesis Inhibitor by Application
1.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application: 2025 vs 2032
1.3.2 Cancer Therapy
1.3.3 Ophthalmic Diseases
1.3.4 Inflammatory and Autoimmune Diseases
1.3.5 Other
1.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue 2021–2032
1.4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales 2021–2032
1.4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Small Molecule Multi-target Angiogenesis Inhibitor Market Competition by Manufacturers
2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2021–2026)
2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Small Molecule Multi-target Angiogenesis Inhibitor, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Product Types and Applications
2.7 Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Date of Entry into the Industry
2.8 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Competitive Situation and Trends
2.8.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Small Molecule Multi-target Angiogenesis Inhibitor Players Market Share by Revenue
2.8.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Scenario by Region
3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021–2032
3.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021–2026
3.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2027–2032
3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021–2032
3.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021–2026
3.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2027–2032
3.4 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.4.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.4.3 North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.5.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.5.3 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021–2032)
3.6.3 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.7.3 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.8.3 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021–2032)
4.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021–2026)
4.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2027–2032)
4.1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021–2032)
4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021–2032)
4.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021–2026)
4.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2027–2032)
4.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021–2032)
4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Type (2021–2032)
5 Segment by Application
5.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021–2032)
5.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021–2026)
5.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2027–2032)
5.1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021–2032)
5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021–2032)
5.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021–2026)
5.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2027–2032)
5.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021–2032)
5.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 TWi Pharmaceuticals
6.3.1 TWi Pharmaceuticals Company Information
6.3.2 TWi Pharmaceuticals Description and Business Overview
6.3.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.3.5 TWi Pharmaceuticals Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 AstraZeneca.
6.6.1 AstraZeneca. Company Information
6.6.2 AstraZeneca. Description and Business Overview
6.6.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.6.5 AstraZeneca. Recent Developments/Updates
6.7 Sanofi
6.7.1 Sanofi Company Information
6.7.2 Sanofi Description and Business Overview
6.7.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Exelixis
6.8.1 Exelixis Company Information
6.8.2 Exelixis Description and Business Overview
6.8.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.8.5 Exelixis Recent Developments/Updates
6.9 Boehringer Ingelheim
6.9.1 Boehringer Ingelheim Company Information
6.9.2 Boehringer Ingelheim Description and Business Overview
6.9.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.9.5 Boehringer Ingelheim Recent Developments/Updates
6.10 Eisai
6.10.1 Eisai Company Information
6.10.2 Eisai Description and Business Overview
6.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.10.5 Eisai Recent Developments/Updates
6.11 Janssen Biotech
6.11.1 Janssen Biotech Company Information
6.11.2 Janssen Biotech Description and Business Overview
6.11.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.11.5 Janssen Biotech Recent Developments/Updates
6.12 Jiangsu Hengrui Pharmaceuticals
6.12.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.12.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.12.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.13 Chia Tai Tianqing
6.13.1 Chia Tai Tianqing Company Information
6.13.2 Chia Tai Tianqing Description and Business Overview
6.13.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.13.5 Chia Tai Tianqing Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Chain Analysis
7.2 Small Molecule Multi-target Angiogenesis Inhibitor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process Analysis
7.4 Small Molecule Multi-target Angiogenesis Inhibitor Sales and Marketing
7.4.1 Small Molecule Multi-target Angiogenesis Inhibitor Sales Channels
7.4.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors
7.5 Small Molecule Multi-target Angiogenesis Inhibitor Customer Analysis
8 Small Molecule Multi-target Angiogenesis Inhibitor Market Dynamics
8.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends
8.2 Small Molecule Multi-target Angiogenesis Inhibitor Market Drivers
8.3 Small Molecule Multi-target Angiogenesis Inhibitor Market Challenges
8.4 Small Molecule Multi-target Angiogenesis Inhibitor Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Small Molecule Multi-target Angiogenesis Inhibitor by Type
1.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type: 2025 vs 2032
1.2.2 Sorafenib
1.2.3 Sunitinib
1.2.4 Apatinib
1.2.5 Anlotinib
1.2.6 Lenvatinib
1.2.7 Vandetanib
1.2.8 Cabozantinib
1.2.9 Pazopanib
1.2.10 Axitinib
1.3 Small Molecule Multi-target Angiogenesis Inhibitor by Application
1.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application: 2025 vs 2032
1.3.2 Cancer Therapy
1.3.3 Ophthalmic Diseases
1.3.4 Inflammatory and Autoimmune Diseases
1.3.5 Other
1.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue 2021–2032
1.4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales 2021–2032
1.4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Small Molecule Multi-target Angiogenesis Inhibitor Market Competition by Manufacturers
2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2021–2026)
2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Small Molecule Multi-target Angiogenesis Inhibitor, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Product Types and Applications
2.7 Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Date of Entry into the Industry
2.8 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Competitive Situation and Trends
2.8.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Small Molecule Multi-target Angiogenesis Inhibitor Players Market Share by Revenue
2.8.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Scenario by Region
3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021–2032
3.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021–2026
3.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2027–2032
3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021–2032
3.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021–2026
3.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2027–2032
3.4 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.4.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.4.3 North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.5.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.5.3 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021–2032)
3.6.3 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.7.3 Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021–2032)
3.8.3 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021–2032)
4.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021–2026)
4.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2027–2032)
4.1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021–2032)
4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021–2032)
4.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021–2026)
4.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2027–2032)
4.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021–2032)
4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Type (2021–2032)
5 Segment by Application
5.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021–2032)
5.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021–2026)
5.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2027–2032)
5.1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021–2032)
5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021–2032)
5.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021–2026)
5.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2027–2032)
5.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021–2032)
5.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 TWi Pharmaceuticals
6.3.1 TWi Pharmaceuticals Company Information
6.3.2 TWi Pharmaceuticals Description and Business Overview
6.3.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.3.5 TWi Pharmaceuticals Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 AstraZeneca.
6.6.1 AstraZeneca. Company Information
6.6.2 AstraZeneca. Description and Business Overview
6.6.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.6.5 AstraZeneca. Recent Developments/Updates
6.7 Sanofi
6.7.1 Sanofi Company Information
6.7.2 Sanofi Description and Business Overview
6.7.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Exelixis
6.8.1 Exelixis Company Information
6.8.2 Exelixis Description and Business Overview
6.8.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.8.5 Exelixis Recent Developments/Updates
6.9 Boehringer Ingelheim
6.9.1 Boehringer Ingelheim Company Information
6.9.2 Boehringer Ingelheim Description and Business Overview
6.9.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.9.5 Boehringer Ingelheim Recent Developments/Updates
6.10 Eisai
6.10.1 Eisai Company Information
6.10.2 Eisai Description and Business Overview
6.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.10.5 Eisai Recent Developments/Updates
6.11 Janssen Biotech
6.11.1 Janssen Biotech Company Information
6.11.2 Janssen Biotech Description and Business Overview
6.11.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.11.5 Janssen Biotech Recent Developments/Updates
6.12 Jiangsu Hengrui Pharmaceuticals
6.12.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.12.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.12.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.13 Chia Tai Tianqing
6.13.1 Chia Tai Tianqing Company Information
6.13.2 Chia Tai Tianqing Description and Business Overview
6.13.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
6.13.5 Chia Tai Tianqing Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Chain Analysis
7.2 Small Molecule Multi-target Angiogenesis Inhibitor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process Analysis
7.4 Small Molecule Multi-target Angiogenesis Inhibitor Sales and Marketing
7.4.1 Small Molecule Multi-target Angiogenesis Inhibitor Sales Channels
7.4.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors
7.5 Small Molecule Multi-target Angiogenesis Inhibitor Customer Analysis
8 Small Molecule Multi-target Angiogenesis Inhibitor Market Dynamics
8.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends
8.2 Small Molecule Multi-target Angiogenesis Inhibitor Market Drivers
8.3 Small Molecule Multi-target Angiogenesis Inhibitor Market Challenges
8.4 Small Molecule Multi-target Angiogenesis Inhibitor Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Competitive Situation by Manufacturers in 2025
Table 4. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Small Molecule Multi-target Angiogenesis Inhibitor, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Product Types and Applications
Table 12. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Companies by Tier (Tier 1, Tier 2, Tier 3), based on Small Molecule Multi-target Angiogenesis Inhibitor Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2021–2026
Table 18. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021–2026)
Table 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2027–2032
Table 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2027–2032)
Table 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2021–2026
Table 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021–2026)
Table 23. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2027–2032
Table 24. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2027–2032)
Table 25. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 27. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 28. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 29. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 32. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 33. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 42. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 43. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 50. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Type (2021–2026)
Table 51. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Type (2027–2032)
Table 52. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021–2026)
Table 53. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2027–2032)
Table 54. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021–2026)
Table 57. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2027–2032)
Table 58. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2021–2026)
Table 59. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2027–2032)
Table 60. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Application (2021–2026)
Table 61. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Application (2027–2032)
Table 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021–2026)
Table 63. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2027–2032)
Table 64. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021–2026)
Table 67. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2027–2032)
Table 68. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2021–2026)
Table 69. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 74. Bayer Recent Developments/Updates
Table 75. Teva Company Information
Table 76. Teva Description and Business Overview
Table 77. Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Teva Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 79. Teva Recent Developments/Updates
Table 80. TWi Pharmaceuticals Company Information
Table 81. TWi Pharmaceuticals Description and Business Overview
Table 82. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 84. TWi Pharmaceuticals Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 94. Novartis Recent Developments/Updates
Table 95. AstraZeneca. Company Information
Table 96. AstraZeneca. Description and Business Overview
Table 97. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 99. AstraZeneca. Recent Developments/Updates
Table 100. Sanofi Company Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Exelixis Company Information
Table 106. Exelixis Description and Business Overview
Table 107. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 109. Exelixis Recent Developments/Updates
Table 110. Boehringer Ingelheim Company Information
Table 111. Boehringer Ingelheim Description and Business Overview
Table 112. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 114. Boehringer Ingelheim Recent Developments/Updates
Table 115. Eisai Company Information
Table 116. Eisai Description and Business Overview
Table 117. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 119. Eisai Recent Developments/Updates
Table 120. Janssen Biotech Company Information
Table 121. Janssen Biotech Description and Business Overview
Table 122. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 124. Janssen Biotech Recent Developments/Updates
Table 125. Jiangsu Hengrui Pharmaceuticals Company Information
Table 126. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 127. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 129. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 130. Chia Tai Tianqing Company Information
Table 131. Chia Tai Tianqing Description and Business Overview
Table 132. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 134. Chia Tai Tianqing Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Small Molecule Multi-target Angiogenesis Inhibitor Distributors List
Table 138. Small Molecule Multi-target Angiogenesis Inhibitor Customers List
Table 139. Small Molecule Multi-target Angiogenesis Inhibitor Market Trends
Table 140. Small Molecule Multi-target Angiogenesis Inhibitor Market Drivers
Table 141. Small Molecule Multi-target Angiogenesis Inhibitor Market Challenges
Table 142. Small Molecule Multi-target Angiogenesis Inhibitor Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Small Molecule Multi-target Angiogenesis Inhibitor
Figure 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Type: 2025 & 2032
Figure 4. Sorafenib Product Picture
Figure 5. Sunitinib Product Picture
Figure 6. Apatinib Product Picture
Figure 7. Anlotinib Product Picture
Figure 8. Lenvatinib Product Picture
Figure 9. Vandetanib Product Picture
Figure 10. Cabozantinib Product Picture
Figure 11. Pazopanib Product Picture
Figure 12. Axitinib Product Picture
Figure 13. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application (US$ Million), 2021–2032
Figure 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Application: 2025 & 2032
Figure 15. Cancer Therapy
Figure 16. Ophthalmic Diseases
Figure 17. Inflammatory and Autoimmune Diseases
Figure 18. Other
Figure 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (US$ Million), 2021–2032
Figure 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), 2021–2032
Figure 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit), 2021–2032
Figure 23. Small Molecule Multi-target Angiogenesis Inhibitor Report Years Considered
Figure 24. Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Manufacturers in 2025
Figure 25. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Manufacturers in 2025
Figure 26. Top 5 and Top 10 Global Small Molecule Multi-target Angiogenesis Inhibitor Players: Market Share by Revenue in Small Molecule Multi-target Angiogenesis Inhibitor in 2025
Figure 27. Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 28. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 29. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 30. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 31. United States Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Canada Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 34. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 35. Germany Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. France Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. U.K. Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Italy Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Russia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021–2032)
Figure 41. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021–2032)
Figure 42. China Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Japan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. India Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Australia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. China Taiwan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 50. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 51. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Argentina Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Colombia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 56. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 57. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. UAE Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Global Sales Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Type (2021–2032)
Figure 61. Global Revenue Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Type (2021–2032)
Figure 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2021–2032)
Figure 63. Global Sales Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Application (2021–2032)
Figure 64. Global Revenue Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Application (2021–2032)
Figure 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2021–2032)
Figure 66. Small Molecule Multi-target Angiogenesis Inhibitor Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Table 1. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Competitive Situation by Manufacturers in 2025
Table 4. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Small Molecule Multi-target Angiogenesis Inhibitor, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Product Types and Applications
Table 12. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Companies by Tier (Tier 1, Tier 2, Tier 3), based on Small Molecule Multi-target Angiogenesis Inhibitor Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2021–2026
Table 18. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021–2026)
Table 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2027–2032
Table 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2027–2032)
Table 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2021–2026
Table 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021–2026)
Table 23. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2027–2032
Table 24. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2027–2032)
Table 25. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 27. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 28. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 29. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 32. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 33. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 42. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 43. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 50. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Type (2021–2026)
Table 51. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Type (2027–2032)
Table 52. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021–2026)
Table 53. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2027–2032)
Table 54. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021–2026)
Table 57. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2027–2032)
Table 58. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2021–2026)
Table 59. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2027–2032)
Table 60. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Application (2021–2026)
Table 61. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Application (2027–2032)
Table 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021–2026)
Table 63. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2027–2032)
Table 64. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021–2026)
Table 67. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2027–2032)
Table 68. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2021–2026)
Table 69. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 74. Bayer Recent Developments/Updates
Table 75. Teva Company Information
Table 76. Teva Description and Business Overview
Table 77. Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Teva Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 79. Teva Recent Developments/Updates
Table 80. TWi Pharmaceuticals Company Information
Table 81. TWi Pharmaceuticals Description and Business Overview
Table 82. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 84. TWi Pharmaceuticals Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 94. Novartis Recent Developments/Updates
Table 95. AstraZeneca. Company Information
Table 96. AstraZeneca. Description and Business Overview
Table 97. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 99. AstraZeneca. Recent Developments/Updates
Table 100. Sanofi Company Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Exelixis Company Information
Table 106. Exelixis Description and Business Overview
Table 107. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 109. Exelixis Recent Developments/Updates
Table 110. Boehringer Ingelheim Company Information
Table 111. Boehringer Ingelheim Description and Business Overview
Table 112. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 114. Boehringer Ingelheim Recent Developments/Updates
Table 115. Eisai Company Information
Table 116. Eisai Description and Business Overview
Table 117. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 119. Eisai Recent Developments/Updates
Table 120. Janssen Biotech Company Information
Table 121. Janssen Biotech Description and Business Overview
Table 122. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 124. Janssen Biotech Recent Developments/Updates
Table 125. Jiangsu Hengrui Pharmaceuticals Company Information
Table 126. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 127. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 129. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 130. Chia Tai Tianqing Company Information
Table 131. Chia Tai Tianqing Description and Business Overview
Table 132. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 134. Chia Tai Tianqing Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Small Molecule Multi-target Angiogenesis Inhibitor Distributors List
Table 138. Small Molecule Multi-target Angiogenesis Inhibitor Customers List
Table 139. Small Molecule Multi-target Angiogenesis Inhibitor Market Trends
Table 140. Small Molecule Multi-target Angiogenesis Inhibitor Market Drivers
Table 141. Small Molecule Multi-target Angiogenesis Inhibitor Market Challenges
Table 142. Small Molecule Multi-target Angiogenesis Inhibitor Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Small Molecule Multi-target Angiogenesis Inhibitor
Figure 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Type: 2025 & 2032
Figure 4. Sorafenib Product Picture
Figure 5. Sunitinib Product Picture
Figure 6. Apatinib Product Picture
Figure 7. Anlotinib Product Picture
Figure 8. Lenvatinib Product Picture
Figure 9. Vandetanib Product Picture
Figure 10. Cabozantinib Product Picture
Figure 11. Pazopanib Product Picture
Figure 12. Axitinib Product Picture
Figure 13. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application (US$ Million), 2021–2032
Figure 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Application: 2025 & 2032
Figure 15. Cancer Therapy
Figure 16. Ophthalmic Diseases
Figure 17. Inflammatory and Autoimmune Diseases
Figure 18. Other
Figure 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (US$ Million), 2021–2032
Figure 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), 2021–2032
Figure 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit), 2021–2032
Figure 23. Small Molecule Multi-target Angiogenesis Inhibitor Report Years Considered
Figure 24. Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Manufacturers in 2025
Figure 25. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Manufacturers in 2025
Figure 26. Top 5 and Top 10 Global Small Molecule Multi-target Angiogenesis Inhibitor Players: Market Share by Revenue in Small Molecule Multi-target Angiogenesis Inhibitor in 2025
Figure 27. Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 28. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 29. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 30. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 31. United States Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Canada Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 34. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 35. Germany Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. France Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. U.K. Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Italy Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Russia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021–2032)
Figure 41. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021–2032)
Figure 42. China Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Japan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. India Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Australia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. China Taiwan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 50. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 51. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Argentina Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Colombia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 56. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 57. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. UAE Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Global Sales Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Type (2021–2032)
Figure 61. Global Revenue Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Type (2021–2032)
Figure 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2021–2032)
Figure 63. Global Sales Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Application (2021–2032)
Figure 64. Global Revenue Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Application (2021–2032)
Figure 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2021–2032)
Figure 66. Small Molecule Multi-target Angiogenesis Inhibitor Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232